(Q42211021)

18 October 2017

title

A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice (English)

1 reference

18 October 2017

0 references

1 reference

Zhiqiang Ku

1

1 reference

18 October 2017

Qingwei Liu

2

1 reference

18 October 2017

Xiaohua Ye

3

1 reference

18 October 2017

Yicun Cai

4

1 reference

18 October 2017

Xiaoli Wang

5

1 reference

18 October 2017

Jinping Shi

6

1 reference

18 October 2017

Dapeng Li

7

1 reference

18 October 2017

Xia Jin

8

1 reference

18 October 2017

Wenqi An

9

1 reference

18 October 2017

Zhong Huang

10

1 reference

18 October 2017

language of work or name

English

0 references

publication date

17 June 2014

1 reference

18 October 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

18 October 2017

volume

32

1 reference

18 October 2017

issue

34

1 reference

18 October 2017

page(s)

4296-4303

1 reference

Human enterovirus 71 and hand, foot and mouth disease.

18 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Comparison of enterovirus 71 and coxsackie-virus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Genetic diversity of coxsackievirus A16 associated with hand, foot, and mouth disease epidemics in Japan from 1983 to 2003

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

An overview of the evolution of enterovirus 71 and its clinical and public health significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Construction and characterization of an infectious clone of coxsackievirus A16.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Virology, epidemiology, pathogenesis, and control of enterovirus 71.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Diseases caused by enterovirus 71 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

EV71: an emerging infectious disease vaccine target in the Far East?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Development of enterovirus 71 vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Progress on the research and development of human enterovirus 71 (EV71) vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Fatal infection in an infant associated with Coxsackie virus group A, type 16.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Myocarditis possibly due to Coxsackie group A, type 16, virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

FATAL COXSACKIEVIRUS A16 INFECTION

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Fatal coxsackievirus A-16 pneumonitis in adult

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Rhombencephalitis and coxsackievirus A16

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Distribution of enteroviruses in hospitalized children with hand, foot and mouth disease and relationship between pathogens and nervous system complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Challenges to licensure of enterovirus 71 vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

A neonatal mouse model of coxsackievirus A16 for vaccine evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Virus-like particles produced in Saccharomyces cerevisiae elicit protective immunity against Coxsackievirus A16 in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Virus-like particles as immunogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Virus-like particles: flexible platforms for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Detection, characterization and quantitation of coxsackievirus A16 using polyclonal antibodies against recombinant capsid subunit proteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Characterization of enterovirus 71 capsids using subunit protein-specific polyclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Identification of conserved neutralizing linear epitopes within the VP1 protein of coxsackievirus A16.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Development of murine monoclonal antibodies with potent neutralization effects on enterovirus 71.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Challenges for the formulation of a universal vaccine against dengue.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Dengue vaccines: progress and challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Human IgG subclasses against enterovirus Type 71: neutralization versus antibody dependent enhancement of infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Antibody dependent enhancement infection of enterovirus 71 in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Subneutralizing antibodies to enterovirus 71 induce antibody-dependent enhancement of infection in newborn mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

Enterovirus 71 Infection of Monocytes with Antibody-Dependent Enhancement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.06.025

10.1016/J.VACCINE.2014.06.025

7 January 2021

Identifiers

DOI

1 reference

18 October 2017

1 reference